 Halozyme Therapeutics Inc NASDAQ: HALO reported Q3 revenue of 115.8 million compared to 65.3 million a year ago, beating the consensus of 101.94 million. The increase is attributable to higher royalty revenue from subcutaneous Darzalex daratumumab and increased product sales. 